Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

NCT06358703•US Thrombotic Microangiopathy Alliance

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Immune Thrombotic Thrombocytopenia

Interventions

Caplacizumab

Locations

United States

Locations (1)

USTMA

Groveport, Ohio, United States

Key Dates

Start Date

December 1, 2024

Primary Completion Date

May 1, 2027

Completion Date

May 1, 2028

Last Updated

November 13, 2024

Sponsors

Lead Sponsor

US Thrombotic Microangiopathy Alliance

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions